Erasca, Inc.
General ticker "ERAS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $4.4B (TTM average)
Erasca, Inc. follows the US Stock Market performance with the rate: 21.6%.
Estimated limits based on current volatility of 5.3%: low 1.32$, high 1.47$
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.55$, 4.31$]
- 2025-12-31 to 2026-12-31 estimated range: [1.11$, 3.25$]
Financial Metrics affecting the ERAS estimates:
- Negative: Non-GAAP EPS, $ of -0.74 <= 0.04
- Negative: Operating cash flow per share per price, % of -1.66 <= 1.79
- Negative: negative Net income
- Negative: Industry operating cash flow per share per price (median), % of -21.10 <= 2.82
- Negative: negative Operating income
- Negative: Shareholder equity ratio, % of 84.27 > 63.75
Short-term ERAS quotes
Long-term ERAS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $247.45MM | $141.53MM | $179.59MM |
| Operating Income | $-247.45MM | $-141.53MM | $-179.59MM |
| Non-Operating Income | $4.64MM | $16.48MM | $17.94MM |
| R&D Expense | $214.46MM | $103.82MM | $137.86MM |
| Income(Loss) | $-242.81MM | $-125.04MM | $-161.65MM |
| Profit(Loss)* | $-238.16MM | $-125.04MM | $-161.65MM |
| Stockholders Equity | $411.85MM | $316.69MM | $423.50MM |
| Assets | $514.91MM | $395.30MM | $502.53MM |
| Operating Cash Flow | $-103.26MM | $-101.22MM | $-109.42MM |
| Capital expenditure | $16.55MM | $1.77MM | $0.06MM |
| Investing Cash Flow | $-71.08MM | $-91.22MM | $-156.62MM |
| Financing Cash Flow | $98.08MM | $1.29MM | $240.70MM |
| Earnings Per Share** | $-0.24 | $-0.10 | $-0.07 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.